Active-Control, Multicenter, Randomized, Open-Label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese

Trial Profile

Active-Control, Multicenter, Randomized, Open-Label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Apixaban (Primary) ; Heparin; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Adverse reactions; Registrational
  • Acronyms AMPLIFY-J
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Sep 2016 Results of this and two other trial (AMPLIFY and AMPLIFY-EXT) published in the Drugs (2016).
    • 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top